Angioedema and ace inhibitors
Pro Research Analysisby 
Searched over 200M research papers
Angioedema and ACE Inhibitors: Pathophysiology, Incidence, and Treatment
Introduction to ACE Inhibitor-Induced Angioedema
Angiotensin-converting enzyme inhibitors (ACE inhibitors) are commonly prescribed medications for hypertension and heart failure. However, they are associated with a rare but potentially life-threatening side effect: angioedema. This condition involves swelling, typically in the face, lips, tongue, and upper airways, and can lead to airway obstruction 245.
Pathophysiology of ACE Inhibitor-Induced Angioedema
The pathogenesis of ACE inhibitor-induced angioedema primarily involves the accumulation of bradykinin, a peptide that promotes vasodilation and increased vascular permeability. ACE inhibitors block the degradation of bradykinin, leading to its accumulation and subsequent angioedema 245. Other mediators such as substance P and prostaglandins may also play a role 45. Genetic predispositions, including certain single nucleotide polymorphisms, have been suggested to contribute to the risk of developing angioedema .
Incidence and Risk Factors
The incidence of angioedema in patients taking ACE inhibitors ranges from 0.1% to 0.7% 245. Certain populations are at higher risk, including African Americans, women, older individuals, smokers, and those with a history of drug rash or seasonal allergies 247. The risk is also higher in patients with heart failure compared to those with hypertension or coronary artery disease without heart failure .
Clinical Presentation and Diagnosis
Angioedema typically presents with sudden swelling of the face, lips, tongue, and upper airways, which can lead to airway obstruction and require emergency intervention 245. Diagnosis is primarily clinical, based on the characteristic presentation and history of ACE inhibitor use 24.
Treatment Options
Immediate Management
The first step in managing ACE inhibitor-induced angioedema is to discontinue the offending drug immediately 245. Acute management focuses on protecting the airway, which may involve endotracheal intubation or tracheotomy in severe cases 245. Standard treatments include antihistamines, corticosteroids, and epinephrine, although their efficacy is limited 245.
Icatibant for Rapid Resolution
Icatibant, a selective bradykinin B2 receptor antagonist, has shown promise in reducing the time to resolution of angioedema symptoms. In a randomized trial, icatibant significantly shortened the median time to complete resolution of edema compared to standard therapy with prednisolone and clemastine (8.0 hours vs. 27.1 hours) . However, another study did not find a significant difference in time-to-resolution between icatibant and placebo, suggesting that its efficacy may vary among different populations .
Alternative Antihypertensive Therapy
Patients who experience angioedema with ACE inhibitors should not be re-challenged with this class of drugs due to the high risk of recurrence 245. Angiotensin receptor blockers (ARBs) are often considered as an alternative, although they also carry a risk of angioedema, albeit lower than that of ACE inhibitors 37. The risk of angioedema with ARBs in patients with a history of ACE inhibitor-induced angioedema ranges from 0% to 9.2% .
Conclusion
ACE inhibitor-induced angioedema is a rare but serious adverse effect that requires prompt recognition and management. The pathophysiology involves the accumulation of bradykinin and other mediators, leading to increased vascular permeability and swelling. Immediate discontinuation of the ACE inhibitor and acute symptomatic treatment are crucial. Icatibant has shown potential in reducing symptom resolution time, although its efficacy may vary. Patients with a history of ACE inhibitor-induced angioedema should avoid re-challenge and may consider ARBs as an alternative, with careful monitoring for recurrence.
Sources and full results
Most relevant research papers on this topic
A randomized trial of icatibant in ACE-inhibitor-induced angioedema.
Icatibant significantly shorterens the time to complete resolution of edema in patients with ACE-inhibitor-induced angioedema compared to standard therapy with glucocorticoid and antihistamine.
ACE Inhibitor-Induced Angioedema: a Review
ACE inhibitors are frequently used but associated with angioedema, which should be avoided in high-risk individuals and treated with early diagnosis, tracheal intubation, and avoidance of re-challenge.
Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors.
Angioedema risk is higher with ACE inhibitors than with ARBs and DRIs, and is higher in heart failure patients compared to those without heart failure.
Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy
Cough occurs in 5% to 20% of ACE inhibitor patients and angioedema occurs in 0.1% to 0.2%, with treatment involving airway protection, antihistamines, and corticosteroids.
Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis.
The risk of developing angioedema after taking an ACE-I and an ARB is between 2% and 17%, with a 0% to 9.2% risk for confirmed angioedema.
DOI